CN102170898A - 用于辐射暴露治疗的组合物和方法 - Google Patents

用于辐射暴露治疗的组合物和方法 Download PDF

Info

Publication number
CN102170898A
CN102170898A CN2009801387748A CN200980138774A CN102170898A CN 102170898 A CN102170898 A CN 102170898A CN 2009801387748 A CN2009801387748 A CN 2009801387748A CN 200980138774 A CN200980138774 A CN 200980138774A CN 102170898 A CN102170898 A CN 102170898A
Authority
CN
China
Prior art keywords
mdp
radiation
microgranule
compositions
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801387748A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·B·格尔德
吉莲·艾利森·韦伯斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Therapeutics Ltd
Original Assignee
Innate Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Therapeutics Ltd filed Critical Innate Therapeutics Ltd
Publication of CN102170898A publication Critical patent/CN102170898A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1094—Shielding, protecting against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2009801387748A 2008-09-30 2009-09-30 用于辐射暴露治疗的组合物和方法 Pending CN102170898A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ571665A NZ571665A (en) 2008-09-30 2008-09-30 Compositions and methods for treatment of radiation exposure utilising cross-linked muramyl dipeptide microparticles
NZ571665 2008-09-30
PCT/NZ2009/000207 WO2010039048A1 (en) 2008-09-30 2009-09-30 Compositions and methods for treatment of radiation exposure

Publications (1)

Publication Number Publication Date
CN102170898A true CN102170898A (zh) 2011-08-31

Family

ID=42073685

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801387748A Pending CN102170898A (zh) 2008-09-30 2009-09-30 用于辐射暴露治疗的组合物和方法

Country Status (10)

Country Link
US (1) US10232010B2 (enExample)
EP (1) EP2349311B1 (enExample)
JP (2) JP6053283B2 (enExample)
CN (1) CN102170898A (enExample)
AU (1) AU2009300442B2 (enExample)
BR (1) BRPI0913783A2 (enExample)
CA (1) CA2738622C (enExample)
ES (1) ES2435438T3 (enExample)
NZ (1) NZ571665A (enExample)
WO (1) WO2010039048A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108273038A (zh) * 2018-03-16 2018-07-13 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN111060697A (zh) * 2019-02-24 2020-04-24 中国疾病预防控制中心辐射防护与核安全医学所 一种利用hmgb1的小肠放射性损伤标记方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
WO2022150763A1 (en) * 2021-01-11 2022-07-14 The George Washington University Nanoparticle-mediated immune cell manufacture and uses thereof
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234078A (zh) * 1996-10-10 1999-11-03 探针国际公司 治疗病毒感染的组合物及方法
WO2000024378A1 (en) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions of microspheres for wound healing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4815446A (en) * 1985-05-09 1989-03-28 Alpha Therapeutic Corporation Process for treating metastasis of cancerous tumors
AU686660B2 (en) * 1993-08-11 1998-02-12 Jenner Technologies Prostatic cancer vaccine
GB9320820D0 (en) * 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
JP5662309B2 (ja) * 2008-04-01 2015-01-28 イネイト・イムノセラピューティクス・リミテッド 腫瘍性疾患を治療するための組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234078A (zh) * 1996-10-10 1999-11-03 探针国际公司 治疗病毒感染的组合物及方法
WO2000024378A1 (en) * 1998-10-23 2000-05-04 Polyheal Ltd Compositions of microspheres for wound healing

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
B.B.C.YOUAN: "Protein-loaded poly(e-caprolactone) microparticles.II. Muramyl dipeptide for oral controlled release of adjuvant", 《J. MICROENCAPSULATION》 *
ICHIOR AZUMA: "REVIEW: INDUCER OF CYTOKINES IN VIVO: OVERVIEW OF FIELD AND ROMURTIDE EXPERIENCE", 《INT. J. LMMUNOPHARMAC.》 *
ICHIOR AZUMA: "Synthetic immunoadjuvants:application to non-specific host stimulation and potentiation of vaccine immunogenicity", 《VACCINE》 *
JAROSLAV TURANEK ET AL.: "STIMULATION OF HAEMOPOIESIS AND PROTECTION OF MICE AGAINST RADIATION INJURY BY SYNTHETIC ANALOGUES OF MURAMYLDIPEPTIDE INCORPORATED IN LIPOSOMES", 《INT. J. LMMUNOPHARMAC.》 *
NAVNEET PURI ET AL.: "An investigation of the intradermal route as an e€ective means of immunization for microparticulate vaccine delivery systems", 《VACCINE》 *
钟英英: "天然免疫调节肽的研究概况", 《重庆科技学院学报（自然科学版）》 *
齐子荣: "胞壁酰二肽的生物学作用", 《中国人民解放军军事医学科学院院刊》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108273038A (zh) * 2018-03-16 2018-07-13 中国人民解放军军事科学院军事医学研究院 防治肠型放射病的药物组合物
CN111060697A (zh) * 2019-02-24 2020-04-24 中国疾病预防控制中心辐射防护与核安全医学所 一种利用hmgb1的小肠放射性损伤标记方法

Also Published As

Publication number Publication date
US20110236346A1 (en) 2011-09-29
EP2349311A4 (en) 2012-07-04
CA2738622A1 (en) 2010-04-08
EP2349311B1 (en) 2013-08-21
BRPI0913783A2 (pt) 2016-11-01
EP2349311A1 (en) 2011-08-03
JP2012504161A (ja) 2012-02-16
CA2738622C (en) 2016-10-18
ES2435438T3 (es) 2013-12-19
JP6053283B2 (ja) 2016-12-27
NZ571665A (en) 2011-01-28
JP2016026157A (ja) 2016-02-12
AU2009300442A1 (en) 2010-04-08
WO2010039048A1 (en) 2010-04-08
US10232010B2 (en) 2019-03-19
AU2009300442B2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CN102170898A (zh) 用于辐射暴露治疗的组合物和方法
CN107669692A (zh) Mpla在制备电离辐射致肠道损伤防治药物中的应用
WO2018145588A1 (zh) 细胞囊泡制剂与低剂量放疗联合在制备抗肿瘤药物中的应用
JP6150374B2 (ja) 放射線被ばく治療剤及び放射線被ばく治療方法
EP2182987A1 (en) Immune system modulator formulation
Prasanna et al. Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine
CN110075269A (zh) Murabutide在制备电离辐射致骨髓、小肠和脾脏损伤防治药物中应用
Gupta et al. Amelioration of radiation-induced hematological and biochemical alterations by Alstonia scholaris (a medicinal plant) extract
Yu et al. RhG-CSF improves radiation-induced myelosuppression and survival in the canine exposed to fission neutron irradiation
CN100518817C (zh) 恢复造血功能的治疗剂和组合物及其用途
Berk et al. 16, 16-Dimethyl prostaglandin E2 and/or syngeneic bone marrow transplantation increase mouse survival after supra-lethal total body irradiation
CN101505781A (zh) 作为辐射防护物质的乳铁蛋白
Dykes et al. Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor
Srinivasan et al. High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines
Rojas et al. Effects of radiomodifiers on high and low LET responses in vivo
RU2837735C1 (ru) Способ получения препарата для лечения животных при радиационно-кадмиевом поражении
CN1378456A (zh) 用于治疗癌症和其它疾病的化学稳定化亚氯酸盐溶液
Rossof et al. Lithium carbonate enhances granulopoiesis and attenuates cyclophosphamide-induced injury in the dog
CN102614180A (zh) 伊曲康唑在制备治疗多发性骨髓瘤药物中的应用
Nagler et al. Redox metal chelation ameliorates radiation-induced bone marrow toxicity in a mouse model
Chany et al. Aspartate‐assisted immune stimulation: Its importance in antitumor and antiviral protection
Lipski et al. Postirradiation, recovery of hemopoiesis in mice treated with Propionibacterium granulosum
RU2312675C1 (ru) Способ профилактики радиационного поражения
CN118021939A (zh) Bmp4蛋白或其衍生物在制备药物中的用途
CN108904479A (zh) 二烯丙基一硫在制备辐射引起白细胞减少的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110831